The Library
Adjuvant bevacizumab is safe treatment for melanoma patients at high risk of recurrence
Tools
Tools
Tools
Biswas, S., East, C., A'Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, Paul, Middleton, M. (Mark) and Corrie, P. (2008) Adjuvant bevacizumab is safe treatment for melanoma patients at high risk of recurrence. In: 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 Sept 2008. Published in: Annals of Oncology, Vol.19 (Suppl.8). pp. 245-246.
Full text not available from this repository.| Item Type: | Conference Item (UNSPECIFIED) |
|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Faculty of Medicine > Warwick Medical School |
| Library of Congress Subject Headings (LCSH): | Bevacizumab, Melanoma -- Patients, Melanoma -- Treatment, Immunological adjuvants |
| Journal or Publication Title: | Annals of Oncology |
| Publisher: | Oxford University Press |
| ISSN: | 0923-7534 |
| Date: | September 2008 |
| Volume: | Vol.19 |
| Number: | Suppl.8 |
| Number of Pages: | 1 |
| Page Range: | pp. 245-246 |
| Status: | Peer Reviewed |
| Publication Status: | Published |
| Description: | Abstract Book of the 33rd ESMO Congress, Stockholm, Sweden 12-16 September 2008 |
| Title of Event: | 33rd European Society for Medical Oncology Congress |
| Type of Event: | Other |
| Location of Event: | Stockholm, Sweden |
| Date(s) of Event: | 12-16 Sept 2008 |
| URI: | http://wrap.warwick.ac.uk/id/eprint/28854 |
Data sourced from Thomson Reuters' Web of Knowledge
Actions (login required)
 |
View Item |
